More news concerning Teva came last week from the Moody's rating agency, which rates Teva's debt (which totaled $28.9 billion as of the end of 2018). Moody's economists stated that they had conducted a period examination of Teva's debt, and that they had not changed their Ba2 rating - a junk bond rating.
"The rating reflects the significant size of Teva in the both the generics market and the original drugs market, plus its status as the world's largest generics company," Moody's economists write. "The debt repayment and the efforts to cut costs are helping to stabilize the business, while the company faces continued erosion of its profits due to competition with Copaxone by generic versions of the drug in the US. Moody's believes that Teva's leverage will reach a peak of 5.6 (ratio of debt to EBITDA) in 2019, before falling gradually to 4.5 in 2020."
Moody's states that there is a risk that Teva will have to spend unforeseen sums in the coming years on prolonged legal proceedings, including on matters pertaining to opioid products.